Locally advanced or metastatic urothelial bladder cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Most patients with these malignancies have urothelial cancer (UC), also known as transitional cell carcinoma; however, other, less common forms, like squamous cancers, adenocarcinomas, and neuroendocrine tumours, are also documented. Every year, approximately 275,000 cases of bladder cancer are discovered worldwide, and 108,000 people pass away from the condition. 90% of bladder cancers diagnosed in developed nations are TCC. Unprecedented improvements in the treatment of mUC have been made in recent years, and this patient population can now access a variety of cutting-edge therapeutic options. There are still many investigations being conducted into efficient therapeutic strategies.

Description

Malignant neoplasms of the urinary system include cancers of the bladder, renal pelvis, ureter, and urethra; however, they are increasingly recognized in international coding schemes as a single site when detected simultaneously. The majority of patients with these cancers have urothelial cancer (UC), also known as transitional cell carcinoma; however, there are also reports of other, less common forms, including squamous cancers, adenocarcinomas, and neuroendocrine tumors. Bladder cancer is the sixth most common cancer in men in the UK and the ninth most common disease overall. Bladder cancer risk factors include smoking, chemical exposure, and recurrent UTIs.

Locally advanced or metastatic urothelial bladder cancer (Epidemiology)

Every year, approximately 275,000 cases of bladder cancer are discovered worldwide, and 108,000 people pass away from the condition. 90% of bladder cancers diagnosed in developed nations are TCC. Squamous cell carcinomas are the most common type of bladder cancer in developing nations, particularly those in the Middle East and Africa, and they are typically brought on by schistosome infection. In China, urinary tract cancer is thought to most frequently manifest as urothelial carcinoma. In endemic schistosomiasis regions of Africa, particularly in Sudan and Egypt, where CSC accounts for two-thirds to three-quarters of all bladder malignancies, SCC is most prevalent. While the situation has remained unchanged in other regions of Africa, recent studies from Egypt have shown that this trend has reversed as a result of improved schistosomiasis control in the region. It is believed that rising smoking rates helped Egypt make the switch to TCC, which has a stronger association with smoking.

Locally advanced or metastatic urothelial bladder cancer -Current Market Size & Forecast Trends

The market for locally advanced or metastatic urothelial bladder cancer is projected to grow significantly, with estimates indicating an increase from approximately USD 1 billion in 2022 to around USD 5 billion by 2035, reflecting a compound annual growth rate (CAGR) of about 21% during this period. This growth is primarily driven by the rising incidence of bladder cancer, which is particularly prevalent among older populations and those exposed to certain occupational hazards. The increasing adoption of targeted therapies and immunotherapies has also contributed to market expansion, as these treatments offer more effective options for managing advanced disease. The Asia-Pacific region is expected to see the fastest growth due to an aging population and improving healthcare infrastructure, while North America will likely maintain the largest market share due to high healthcare spending and a strong presence of pharmaceutical companies. Overall, the urothelial bladder cancer market is well-positioned for robust growth through 2035, fueled by ongoing advancements in treatment and increased awareness of the disease.

Recent years have seen unprecedented progress in the treatment of mUC, and this patient population now has access to a wide range of cutting-edge therapeutic options. Along with the recent fantastic advancements, there are additional important issues that call for further discussion. The significance of PD-L1 status as a prognostic or predictive marker, the analytical assay, prognostic and predictive biomarkers, and the reason why chemotherapy and immunotherapy combined in the first line context have not demonstrated the anticipated benefit are some of these issues. The sequencing of treatments for advanced urothelial cancer should be guided by the results of numerous investigations into efficient therapeutic strategies that are still being conducted. These investigations should address some important concerns. MFA-370 (Ectin Research AG), Avelumab (Merck KGaA), Atezolizumab (Genentech), Disitamab vedotin (Yantai Rongchang Pharmaceutical), and other important players have the potential to drive the development of the metastatic urothelial bladder cancer market.

Report Highlights

Locally advanced or metastatic urothelial bladder cancer - Current Market Trends

Locally advanced or metastatic urothelial bladder cancer - Current & Forecasted Cases across the G8 Countries

Locally advanced or metastatic urothelial bladder cancer - Market Opportunities and Sales Potential for Agents

Locally advanced or metastatic urothelial bladder cancer - Patient-based Market Forecast to 2035

Locally advanced or metastatic urothelial bladder cancer - Untapped Business Opportunities

Locally advanced or metastatic urothelial bladder cancer - Product Positioning Vis-a-vis Competitors' Products

Locally advanced or metastatic urothelial bladder cancer - KOLs Insight